SERETIDE Plus Tiotropium Versus Individual Components
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effects on lung function of a combination of SERETIDE
50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual
treatments (tiotropium bromide 18mcg once daily alone and SERETIDE 50/500mcg twice daily
alone) in subjects with COPD. The study will utilise a three-way cross-over design with a
2-week wash-out period between each 2-week consecutive treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Tiotropium Bromide